{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,27]],"date-time":"2026-05-27T15:22:30Z","timestamp":1779895350540,"version":"3.53.1"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,10,29]],"date-time":"2024-10-29T00:00:00Z","timestamp":1730160000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2024,10,29]],"date-time":"2024-10-29T00:00:00Z","timestamp":1730160000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-024-76472-0","type":"journal-article","created":{"date-parts":[[2024,10,29]],"date-time":"2024-10-29T08:29:40Z","timestamp":1730190580000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":16,"title":["Nirmatrelvir plus ritonavir reduces COVID-19 hospitalization and prevents long COVID in adult outpatients"],"prefix":"10.1038","volume":"14","author":[{"given":"Fatemeh","family":"Saheb Sharif-Askari","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hawra","family":"Ali Hussain Alsayed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Narjes","family":"Saheb Sharif-Askari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ali","family":"Al Sayed Hussain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saleh","family":"Al-Muhsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rabih","family":"Halwani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,10,29]]},"reference":[{"key":"76472_CR1","unstructured":"http:\/\/www.cdc.gov\/coronavirus\/2019-ncov\/hcp\/clinical-care\/underlyingconditions.html, A.J., 2023."},{"key":"76472_CR2","doi-asserted-by":"publisher","first-page":"1069","DOI":"10.1007\/s42399-020-00363-4","volume":"2","author":"A Sanyaolu","year":"2020","unstructured":"Sanyaolu, A. et al. Comorbidity and its impact on patients with COVID-19. SN Compr. Clin. Med. 2, 1069\u20131076 (2020).","journal-title":"SN Compr. Clin. Med."},{"key":"76472_CR3","doi-asserted-by":"publisher","first-page":"1706","DOI":"10.1038\/s41591-022-01909-w","volume":"28","author":"A Subramanian","year":"2022","unstructured":"Subramanian, A. et al. Symptoms and risk factors for long COVID in non-hospitalized adults. Nat. Med. 28, 1706\u20131714 (2022).","journal-title":"Nat. Med."},{"key":"76472_CR4","unstructured":"US Food and Drug Administration. Emergency use authorization 105. (2021). https:\/\/www.fda.gov\/media\/155049\/download. Accessed 12 December 2022."},{"key":"76472_CR5","unstructured":"https:\/\/www.covid19treatmentguidelines.nih.gov\/tables\/management-of-nonhospitalized-adults-summary\/. Accessed Janauary 6."},{"key":"76472_CR6","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1056\/NEJMoa2116044","volume":"386","author":"A Jayk Bernal","year":"2021","unstructured":"Jayk Bernal, A. et al. Molnupiravir for oral treatment of Covid-19 in nonhospitalized patients. N. Engl. J. Med. 386, 509\u2013520 (2021).","journal-title":"N. Engl. J. Med."},{"key":"76472_CR7","doi-asserted-by":"publisher","first-page":"1586","DOI":"10.1126\/science.abl4784","volume":"374","author":"DR Owen","year":"2021","unstructured":"Owen, D. R. et al. An oral SARS-CoV-2 Mpro inhibitor clinical candidate for the treatment of COVID-19. Science. 374, 1586\u20131593 (2021).","journal-title":"Science"},{"key":"76472_CR8","doi-asserted-by":"publisher","first-page":"18422","DOI":"10.1073\/pnas.1010693107","volume":"107","author":"IF Sevrioukova","year":"2010","unstructured":"Sevrioukova, I. F. & Poulos, T. L. Structure and mechanism of the complex between cytochrome P4503A4 and ritonavir. Proc. Natl. Acad. Sci. 107, 18422\u201318427 (2010).","journal-title":"Proc. Natl. Acad. Sci."},{"key":"76472_CR9","doi-asserted-by":"publisher","first-page":"632","DOI":"10.1016\/S2213-2600(22)00135-7","volume":"10","author":"D Munblit","year":"2022","unstructured":"Munblit, D. et al. Long COVID: aiming for a consensus. Lancet Respirat. Med. 10, 632\u2013634 (2022).","journal-title":"Lancet Respiratory Med."},{"key":"76472_CR10","doi-asserted-by":"publisher","first-page":"e2128568","DOI":"10.1001\/jamanetworkopen.2021.28568","volume":"4","author":"D Groff","year":"2021","unstructured":"Groff, D. et al. Short-term and long-term rates of Postacute Sequelae of SARS-CoV-2 infection: a systematic review. JAMA Netw. Open. 4, e2128568\u2013e2128568 (2021).","journal-title":"JAMA Netw. Open."},{"key":"76472_CR11","doi-asserted-by":"publisher","first-page":"1957","DOI":"10.1038\/s41467-022-29521-z","volume":"13","author":"M Whitaker","year":"2022","unstructured":"Whitaker, M. et al. Persistent COVID-19 symptoms in a community study of 606,434 people in England. Nat. Commun. 13, 1957 (2022).","journal-title":"Nat. Commun."},{"key":"76472_CR12","doi-asserted-by":"publisher","first-page":"881","DOI":"10.1016\/j.cell.2022.01.014","volume":"185","author":"Y Su","year":"2022","unstructured":"Su, Y. et al. Multiple early factors anticipate post-acute COVID-19 sequelae. Cell. 185, 881\u2013895e820 (2022).","journal-title":"Cell"},{"key":"76472_CR13","doi-asserted-by":"publisher","first-page":"1461","DOI":"10.1038\/s41591-022-01840-0","volume":"28","author":"Z Al-Aly","year":"2022","unstructured":"Al-Aly, Z., Bowe, B. & Xie, Y. Long COVID after breakthrough SARS-CoV-2 infection. Nat. Med. 28, 1461\u20131467 (2022).","journal-title":"Nat. Med."},{"key":"76472_CR14","doi-asserted-by":"crossref","unstructured":"Kim, H. et al. Can nirmatrelvir\/ritonavir treatment shorten the duration of COVID-19 isolation? Front. Med. 9 (2022).","DOI":"10.3389\/fmed.2022.988559"},{"key":"76472_CR15","doi-asserted-by":"crossref","unstructured":"Ganatra, S. et al. Oral nirmatrelvir and ritonavir in nonhospitalized vaccinated patients with coronavirus disease 2019 (COVID-19). Clin. Infect. Dis. ciac673 (2022).","DOI":"10.1093\/cid\/ciac673"},{"key":"76472_CR16","doi-asserted-by":"crossref","unstructured":"Najjar-Debbiny, R. et al. Effectiveness of paxlovid in reducing severe coronavirus disease 2019 and mortality in high-risk patients. Clin. Infect. Dis. ciac443 (2022).","DOI":"10.1093\/cid\/ciac443"},{"key":"76472_CR17","doi-asserted-by":"publisher","first-page":"19688","DOI":"10.1038\/s41598-023-46912-4","volume":"13","author":"S Congdon","year":"2023","unstructured":"Congdon, S. et al. Nirmatrelvir\/ritonavir and risk of long COVID symptoms: A retrospective cohort study. Sci. Rep. 13, 19688 (2023).","journal-title":"Sci. Rep."},{"key":"76472_CR18","doi-asserted-by":"publisher","first-page":"554","DOI":"10.1001\/jamainternmed.2023.0743","volume":"183","author":"Y Xie","year":"2023","unstructured":"Xie, Y., Choi, T. & Al-Aly, Z. Association of Treatment with Nirmatrelvir and the risk of Post\u2013COVID-19 Condition. JAMA Int. Med. 183, 554\u2013564 (2023).","journal-title":"JAMA Intern. Med."},{"key":"76472_CR19","unstructured":"Dubai Health Authority. https:\/\/www.dha.gov.ae\/en\/media\/news\/762. Accessed 10\/12\/2023."},{"key":"76472_CR20","unstructured":"Dubai Health Authority. https:\/\/services.dha.gov.ae\/sheryan\/wps\/portal\/home\/circular-details?circularRefNo=CIR-2021-00000039&isPublicCircular=1&fromHome=true. Accessed 1\/02\/2022."},{"key":"76472_CR21","unstructured":"Dubai Health Authority. https:\/\/www.dha.gov.ae\/uploads\/112021\/ef299be5-9980-4389-9a31-80df9eb069fc.pdf, Accessed: 1\/02\/2022."},{"key":"76472_CR22","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1016\/j.puhe.2024.02.031","volume":"230","author":"S Sharif-Askari","year":"2024","unstructured":"Sharif-Askari, S. Risk factors and early preventive measures for long COVID in non-hospitalized patients: Analysis of a large cohort in the United Arab Emirates. Public. Health. 230, 198\u2013206 (2024).","journal-title":"Public. Health"},{"key":"76472_CR23","doi-asserted-by":"crossref","unstructured":"Davis, H. E. et al. Characterizing long COVID in an international cohort: 7 months of symptoms and their impact. eClinicalMedicine 38 (2021).","DOI":"10.1016\/j.eclinm.2021.101019"},{"key":"76472_CR24","doi-asserted-by":"crossref","unstructured":"Aggarwal, N. R. et al. Real-world use of nirmatrelvir\u2013ritonavir in outpatients with COVID-19 during the era of omicron variants including BA.4 and BA.5 in Colorado, USA: A retrospective cohort study. Lancet. Infect. Dis. 23, 696\u2013705 (2023).","DOI":"10.1016\/S1473-3099(23)00011-7"},{"key":"76472_CR25","doi-asserted-by":"publisher","first-page":"E220","DOI":"10.1503\/cmaj.221608","volume":"195","author":"KL Schwartz","year":"2023","unstructured":"Schwartz, K. L. et al. Population-based evaluation of the effectiveness of nirmatrelvir\u2013ritonavir for reducing hospital admissions and mortality from COVID-19. Can. Med. Assoc. J. 195, E220 (2023).","journal-title":"Can. Med. Assoc. J."},{"key":"76472_CR26","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1056\/NEJMc2214302","volume":"388","author":"M Imai","year":"2023","unstructured":"Imai, M. et al. Efficacy of antiviral agents against Omicron subvariants BQ.1.1 and XBB. N. Engl. J. Med. 388, 89\u201391 (2023).","journal-title":"N. Engl. J. Med."},{"key":"76472_CR27","doi-asserted-by":"publisher","first-page":"504","DOI":"10.1016\/S2213-2600(23)00142-X","volume":"11","author":"C Yang","year":"2023","unstructured":"Yang, C., Zhao, H., Esp\u00edn, E. & Tebbutt, S. J. Association of SARS-CoV-2 infection and persistence with long COVID. Lancet Respirat. Med. 11, 504\u2013506 (2023).","journal-title":"Lancet Respiratory Med."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-76472-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-76472-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-76472-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T08:04:39Z","timestamp":1730448279000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-76472-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,29]]},"references-count":27,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["76472"],"URL":"https:\/\/doi.org\/10.1038\/s41598-024-76472-0","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,10,29]]},"assertion":[{"value":"25 January 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 October 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 October 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"25901"}}